Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models.

ABSTRACT: Pediatric diffuse midline gliomas (DMG) with altered H3-K27M are aggressive brain tumors that arise during childhood. Despite advances in genomic knowledge and the significant number of clinical trials testing new targeted therapies, patient outcomes are still poor. Immune checkpoint blockades with small molecules, such as aptamers, are opening new therapeutic options that represent hope for this orphan disease. Here, we demonstrated that a TIM-3 aptamer (TIM-3 Apt) as monotherapy increased the immune infiltration and elicited a strong specific immune response with a tendency to improve the overall survival of treated DMG-bearing mice. Importantly, combining TIM-3 Apt with radiotherapy increased the overall median survival and led to long-term survivor mice in 2 pediatric DMG orthotopic mu

SUBMITTER: Ausejo-Mauleon I 

PROVIDER: S-EPMC11457855 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature